ResMed''s Q3 Earnings Short Of Expectations, Profit Margins Contract
ResMed Inc''s (NYSE: RMD ) Q3 FY22 sales increased by 12% Y|Y ( 14% on a constant currency basis) to $864.5 million, missing the consensus of $897 million. The revenue growth was driven by increased demand for sleep and respiratory care devices and an increased demand following an ongoing recall of rival Koninklijke Philips N.V. (NYSE: PHG ) products. ResMed generated $35 … Full story available on Benzinga.com
ResMed''s Q3 Earnings Short Of Expectations, Profit Margins Contract
ResMed Inc''s (NYSE: RMD ) Q3 FY22 sales increased by 12% Y|Y ( 14% on a constant currency basis) to $864.5 million, missing the consensus of $897 million. The revenue growth was driven by increased demand for sleep and respiratory care devices and an increased demand following an ongoing recall of rival Koninklijke Philips N.V. (NYSE: PHG ) products. ResMed generated $35 … Full story available on Benzinga.com